PMV Pharmaceuticals (NASDAQ:PMVP) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of PMV Pharmaceuticals (NASDAQ:PMVP) in a report released on Tuesday morning, Benzinga reports. They currently have a $5.00 price objective on the stock. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.36) EPS, FY2024 earnings at ($1.03) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.39) EPS, Q3 2025 earnings at ($0.40) EPS, Q4 2025 earnings at ($0.41) EPS and FY2025 earnings at ($1.57) EPS.

Other analysts have also recently issued research reports about the stock. Craig Hallum started coverage on shares of PMV Pharmaceuticals in a research note on Monday, May 13th. They issued a buy rating and a $6.00 price target on the stock. CLSA raised PMV Pharmaceuticals to a strong-buy rating in a research note on Monday, May 13th. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, PMV Pharmaceuticals presently has an average rating of Buy and a consensus price target of $5.75.

PMV Pharmaceuticals Trading Up 1.3 %

Shares of PMVP opened at $1.55 on Tuesday. PMV Pharmaceuticals has a 12-month low of $1.18 and a 12-month high of $7.64. The company has a market capitalization of $79.74 million, a PE ratio of -1.17 and a beta of 1.53. The business’s 50 day moving average is $1.58 and its 200 day moving average is $1.71.

PMV Pharmaceuticals (NASDAQ:PMVP) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.32. Equities research analysts predict that PMV Pharmaceuticals will post -1.17 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC raised its position in PMV Pharmaceuticals by 344.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 9,508 shares of the company’s stock valued at $29,000 after purchasing an additional 7,368 shares during the period. Independent Advisor Alliance purchased a new position in PMV Pharmaceuticals during the fourth quarter worth $39,000. Mirae Asset Global Investments Co. Ltd. bought a new position in PMV Pharmaceuticals during the first quarter valued at $26,000. Public Employees Retirement System of Ohio raised its stake in shares of PMV Pharmaceuticals by 174.2% in the first quarter. Public Employees Retirement System of Ohio now owns 22,757 shares of the company’s stock valued at $39,000 after acquiring an additional 14,457 shares during the period. Finally, Aristides Capital LLC bought a new stake in shares of PMV Pharmaceuticals in the 4th quarter worth about $97,000. Institutional investors own 90.20% of the company’s stock.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.